Illumina (ILMN) Restructuring Costs (2012 - 2022)

Illumina's (ILMN) quarterly Restructuring Costs came in at $609.0 million in Q3 2022, up 7712.5% quarter-over-quarter from -$8.0 million in Q3 2017.

Analysis

Illumina (ILMN) Restructuring Costs (2012 - 2022) Analysis & Trends

Illumina (ILMN) has reported Restructuring Costs for 7 consecutive years, with $609.0 million the latest figure, recorded in Q3 2022.

For the quarter ending Q3 2022, Restructuring Costs changed N/A year-over-year to $609.0 million; the trailing twelve-month figure through Jul 2022 stood at $609.0 million (changed N/A YoY), and the FY2017 full-year result was -$9.0 million, down 147.37% from the prior year.
Restructuring Costs improved to $609.0 million in Q3 2022 per ILMN's latest filing, from -$8.0 million in the prior quarter.
Across five years, Restructuring Costs topped out at $609.0 million in Q3 2022 and bottomed at $609.0 million in Q3 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	241.68 Bn	237.61 Bn	8.34 Bn
2	Danaher	147.34 Bn	142.99 Bn	3.61 Bn
3	Agilent Technologies	43.34 Bn	41.59 Bn	1.04 Bn
4	Illumina	34.58 Bn	33.41 Bn	770.00 Mn
5	Revvity	16.31 Bn	15.29 Bn	416.87 Mn
6	Bio-Techne	11.28 Bn	11.01 Bn	211.39 Mn
7	Bio-Rad Laboratories	10.16 Bn	8.54 Bn	345.80 Mn
8	Repligen	9.77 Bn	8.75 Bn	110.04 Mn
9	10x Genomics	9.45 Bn	8.90 Bn	112.50 Mn
10	Bruker	9.26 Bn	9.04 Bn	416.00 Mn

Historic Data

Download Data